China Longevity Group Company Limited (1863) Fair Value & Analysis
Other · HK · Market cap HK$1.2B
Fair value as of: Aug 13, 2026
From 20 valuation models · updated 3 days ago
Below-average quality, and screening another 51% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (HK$0.6700). The favourable scenario is already priced in.
- Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$1.37 – HK$1.37 · fair‑value band HK$0.5500 – HK$0.6700 · the HK$1.37 price screens above the HK$0.6700 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
China Longevity Group Company Limited (1863) currently trades at HK$1.37, while our model-based Fair Value estimate is HK$0.6700, implying the stock looks roughly 51.1% overvalued today. The Quality Score stands at 46/100 (below-average quality), in the Other sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Net debt stands at HK$546M. The stock trades on a trailing P/E of 22.4 (as of Jul 2, 2026). Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.5500 (bear case) to HK$0.6700 (bull case); at HK$1.37, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Other peers we cover trades at -24% fair-value upside, at -51%, 1863 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 20 models by family
Widest divergence: Multiples (HK$0.7900) versus DCF Models (HK$0.1900). Highest evidence: Residual Income (76).
Notify me when 1863 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 56
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
There is no Profile data available for 1863.HK.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
China Longevity Group Company Limited reported revenue of HK$1.2B in FY2025 versus HK$1.4B in FY2021, a compound −5.0%/yr. Reported net income was HK$43.2M in FY2025, compounding −20.3%/yr from FY2021.
1863 screens 51% overvalued. Compare with Federal Home Loan Mortgage Corporation →
Peer Group
Other · 369 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Other median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Other stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Federal Home Loan Mortgage Corporation FREJO | $15.58 | $51.90 | +233% |
| 533278 533278 | ₹409.15 | ₹660.78 | +62% |
| Nestl?? India Limited 500790 | ₹1,497 | ₹191.93 | -87% |
| ITC Limited 500875 | ₹279.50 | ₹212.74 | -24% |
| Wipro Limited 507685 | ₹183.80 | ₹193.38 | +5% |
| 540376 540376 | ₹4,054 | ₹1,542 | -62% |
| 540777 540777 | ₹537.50 | ₹149.72 | -72% |
| Lupin Limited 500257 | ₹2,265 | ₹1,983 | -12% |
| Dabur India Limited 500096 | ₹413.80 | ₹122.93 | -70% |
| 540719 540719 | ₹1,835 | ₹872.41 | -52% |
Compare China Longevity Group Company Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
Frequently asked questions
Is China Longevity Group Company Limited (1863) overvalued or undervalued?
What is the fair value of 1863?
What is the quality score of 1863?
What is the net profit margin of 1863?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track China Longevity Group Company Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.